作为肺部疾病治疗点的BRD4
Xia Guo1, Ayobami Olajuyin1, Torry A Tucker1
1Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA.
International journal of molecular sciences
|September 9, 2023
概括
基因和端外域 (BET) 蛋白调节基因转录,并与肺部疾病有关. 在临床前模型中,BET抑制剂通过调节关键疾病相关基因,显示出有前途的结果.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
- 肺部病理学 肺部病理学
背景情况:
- 基因和端外域 (BET) 蛋白质是控制基因转录的表观遗传调节者.
- BET蛋白质影响关键的细胞功能,包括增殖,分化,炎症和免疫反应.
- 这些蛋白质与各种人类肺部疾病的发病有关,例如COPD,喘和肺纤维化.
研究的目的:
- 审查BET蛋白质,特别是BRD4在人类主要肺部疾病中的作用.
- 探索BET蛋白参与肺病进展的基础分子机制.
- 总结关于BET抑制剂在肺部疾病中的治疗潜力的临床前发现.
主要方法:
- 对肺部疾病中BET蛋白及其抑制剂的研究进行文献综述.
- 分析涉及BET蛋白在炎症和细胞功能中的分子机制.
- 在各种肺病模型中使用BET抑制剂的研究中检查了临床前数据.
主要成果:
- 在肺部疾病中,BET蛋白质是关键基因的关键调节者,对炎症和细胞过程至关重要.
- 指出BRD4的内在基酸转移酶活性是潜在的显著.
- 临床前研究表明,BET抑制剂在多种肺病模型中具有有益作用.
结论:
- 向BET蛋白质,特别是BRD4,是人类肺部疾病的有前途的治疗策略.
- 调节BET蛋白活性可以影响参与疾病发病的关键基因.
- 对BET抑制剂的进一步研究可能会导致对炎症和纤维性肺部疾病的新治疗方法.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
481
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
481
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
197
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
197
Pulmonary Hypertension: Classification and Pathogenesis
216
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
216
COPD: Management Using Bronchodilators and Corticosteroids
241
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
241
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
199
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
199
Antiasthma Drugs: β2-Adrenoceptor Agonists
295
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
295


